Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update

By Jennifer S. Smith, L. Lindsay, B. Hoots, J. Keys, Silvia Franceschi, Rachel L. Winer, G. Clifford. International Journal of Cancer, 2007

1,732 citations recorded by the source corpus.

Data on human papillomavirus (HPV) type distribution in invasive and pre‐invasive cervical cancer is essential to predict the future impact of HPV16/18 vaccines and HPV‐based screening tests. A meta‐analyses of HPV type distribution in invasive cervical cancer (ICC) and high‐grade squamous intraepithelial lesions (HSIL) identified a total of 14,595 and 7,094 cases, respectively. In ICC, HPV16 was the most common, and HPV18 the second most common, type in all continents. Combined HPV16/18 prevalence among ICC cases was slightly higher in Europe, North America and Australia (74–77%) than in Africa, Asia and South/Central America (65–70%). The next most common HPV types were the same in each continent, namely HPV31, 33, 35, 45, 52 and 58, although their relative importance differed somewhat by region. HPV18 was significantly more prevalent in adeno/adenosquamous carcinoma than in squamous cell carcinoma, with the reverse being true for HPV16, 31, 33, 52 and 58. Among HSIL cases, HPV16/18 prevalence was 52%. However, HPV 16, 18 and 45 were significantly under‐represented, and other high‐risk HPV types significantly over‐represented in HSIL compared to ICC, suggesting differences in type‐specific risks for progression. Data on HPV‐typed ICC and HSIL cases were particularly scarce from large regions of Africa and Central Asia. © 2007 Wiley‐Liss, Inc.

Subfields: Epidemiology, Obstetrics and Gynecology, Surgery

View Paper: https://www.semanticscholar.org/paper/3931addd944e44c2977805e283e9a6bf1d5b9c8f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Silvia Franceschi
2. S. de Sanjosé
3. G. Clifford
4. S. Kjaer
5. Mark Schiffman
6. M. Arbyn
7. M. Stanley

In Obstetrics and Gynecology

1. G. Clifford
2. Silvia Franceschi
3. S. de Sanjosé

In Surgery

1. S. Kjaer
2. Mark Schiffman
3. Silvia Franceschi
4. M. Stanley

Citations in the corpus

• Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. (2008, methodology): “Type-specific HPV prevalence across the spectrum of HPV related cervical diagn squamous intraepithelial lesions; SCC: Squamous cervical carcinoma [1,8,16].”
• Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication (2011, methodology): “In a recent working group at IARC, other types in the high-risk clade (HPV26, 30, 34, 53, 66, 67, 69, 70, 73, 82 and 85) were all classified for cautionary reasons as possibly carcinogenic to humans (Group 2B) even in the absence of adequate epidemiological data on their carcinogenic potential.5,9 O”
• Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women of 30 years and older (2009, background): “The most important of these HPV genotypes are HPV16 and HPV18, which account for 70% of all invasive cervical cancers with minor variations in this percentage between continents.(3) A new paradigm of cervical carcinogenesis replaces an older model of stepwise progression from low-grade to highgrade ”
• Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta‐analysis (2009, background): “By comparison, HPV16 accounts for only approximately half of cervical carcinoma.(25) A stronger predominance of HPV16 than in cervical carcinoma has also been reported in HPV-related head and neck carcinoma.”
• iArc monogrAphs on the evAluAtion oF cArcinogenic risks to humAns (2012, background): “HPV 18 is the second most important cervical carcinogen, responsible for approximately 15% of cervical cancer of all histological types combined (and a higher fraction of adenocarcinomas) (Clifford et al., 2003; Smith et al., 2007).”
• European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition—Summary Document (2010, background): “These HPV types are causally linked with 70% of cervical cancers in Europe [28, 29].”